Recursion Pharmaceuticals, Inc. Class A Common Stock

€3.007
EUR
Last updated on --.
24h volume16.74M
24h highest3.1064 EUR
24h lowest2.9082 EUR
24h Price movement-3.32%

RXRX recent prices

24 Hours
-3.32%-€0.1034
30 days
+3.56%+€0.1034
60 days
+10.79%+€0.29298
90 days
+0.87%+€0.025851

Key data

Previous close3.1107 EUR
Market cap1.64B EUR
Volume16.74M
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)-0.90479 EUR
Net income (FY)-482.36M EUR
Revenue (FY)57.22M EUR
Last report dateMay 6, 2026

About Recursion Pharmaceuticals, Inc. Class A Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
HeadquartersSALT LAKE CITY
Employees (FY)600.00
Revenue per employee (FY)95.37K EUR
Net income per employee (FY)-803.93K EUR
Listed onNasdaq
Official website

RXRX conversion tables

RXRXRXRX
EUREUR
0.5 RXRX1.503 EUR
1 RXRX3.007 EUR
5 RXRX15.03 EUR
10 RXRX30.07 EUR
EUREUR
RXRXRXRX
0.5 EUR0.16626 RXRX
1 EUR0.33252 RXRX
5 EUR1.662 RXRX
10 EUR3.325 RXRX

FAQ

RXRX is trading at €3.007, -3.32% over the last 24 hours. Track live moves on the price chart at the top of this page.
The RXRX stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. RXRX is currently trading at €3.007, -3.32% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on RXRX price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. RXRX's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from RXRX; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against RXRX's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Recursion Pharmaceuticals, Inc. Class A Common Stock's market cap is currently 1.64B EUR. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume16.74M
24h highest3.1064 EUR
24h lowest2.9082 EUR
24h Price movement-3.32%
RXRXRXRX
EUREUR
Start trade with RXRX Perpetual